Program
Tenecteplase
Also written as “tenecteplase”, “rhTNK-tPA” and “GNR-060”.
Its studies are mostly in Myocardial Infarction · Ischemic Stroke · ST Elevation Myocardial Infarction · Stroke · Heart Arrest, led by 4 companies.
Drug pageTenecteplase: every studyAll 98 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheimits history only | 81 open or running | phase 4since Sep 9, 2005 | Sep 7, 2005 | Oct 2, 2027phase 3 · NCT07361302 |
| Hoffmann-La Roche | 50 open or running | phase 3since Nov 2, 2006 | Nov 2, 2006 | none ahead |
| CSPC Pharmaceutical Groupits history only | 21 open or running | phase 4since Jun 12, 2016 | Jun 12, 2016 | Sep 30, 2027phase 3 · NCT07201688 |
| AO GENERIUMits history only | 10 open or running | phase 3since Oct 26, 2022 | Oct 26, 2022 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Hoffmann-La Roche only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 2, 2006First studies: 4 phase 3 studiesFirst studyNCT00396318, NCT00396253, NCT00396032 and 1 more
- Dec 19, 2018Phase 3 study in THROMBOLYSISNCT03785678 · 458 enrolled · United States, Canada
TargetBeta
“Tissue-type plasminogen activator exogenous protein”ChEMBL 37, by rule
Studies
All 5 Hoffmann-La Roche leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03785678THROMBOLYSIS · United States, Canada | 3 | Completed | Feb 28, 2023 | 458 |
| NCT00396318Dysfunctional Central Venous Access Catheters | 3 | Completed | Jun 2008 | 251 |
| NCT00396253Dysfunctional Hemodialysis Catheters | 3 | Completed | Oct 2008 | 223 |
| NCT00396032Renal Insufficiency | 3 | Completed | Dec 2008 | 150 |
| NCT00395876Dysfunctional Central Venous Access Catheters | 3 | Completed | Jun 2008 | 100 |
How it is read
Names in the registry
- “tenecteplase”, 6 entries
- “Tenecteplase”, 5 entries
- “rhTNK-tPA”, 2 entries
- “GNR-060”, 1 entry
- “Full dose TNK-tPA”, 1 entry
Conditions, from the studies’ own filings
- Myocardial Infarction, 5 studies
- Ischemic Stroke, 2 studies
- ST Elevation Myocardial Infarction, 2 studies
- Stroke, 1 study
- Heart Arrest, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.